In a review of clinical studies dating to 2002 with safety data documented in ICU patients who received HES, gelatin, dextran, or albumin, Groeneveld et al. [ 6] demonstrated that impaired coagulation, clinical bleeding, and acute kidney injury (AKI) were frequently reported after HES infusion